Navigation Links
Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer
Date:11/19/2008

atient safety is our top priority, hence we have acted quickly to implement the recommendations of the DMC. Working with our development partner, Takeda, we will continue to evaluate the therapeutic potential of motesanib in non-squamous NSCLC and metastatic breast cancer, as well as in other solid tumors."

"NSCLC continues to be an area where new and effective therapies are needed. We look forward to the follow up recommendations from the DMC in order to chart the best path forward for the development of this molecule," said Nancy Simonian, M.D., chief medical officer, Millennium: The Takeda Oncology Company.

MONET1 (Motesanib NSCLC Efficacy and Tolerability Study) Trial Design

This Phase 3, multicenter, randomized, placebo-controlled, double-blind trial has enrolled 1,100 of 1,240 planned patients with advanced NSCLC. Patients with either squamous or non-squamous NSCLC were allowed in this study. Squamous NSCLC is a histological subtype of NSCLC and accounts for approximately one-third of the study population. The primary endpoint is overall survival, and secondary endpoints include progression-free survival, objective response rate in patients with measurable disease, duration of response and safety. Patients were randomized 1:1 to receive carboplatin and paclitaxel administered every three weeks with or without 125 mg motesanib taken daily.

About Motesanib

Co-developed by Amgen, Takeda Pharmaceutical Company, and Millennium: The Takeda Oncology Company, motesanib is an investigational, highly selective, oral agent that is being evaluated for its ability to inhibit angiogenesis by targeting vascular endothelial growth factor receptors 1, 2 and 3 (VEGFR1-3). It is also under investigation for its potential direct anti-tumor activity by targeting a family of proteins called tyrosine kinases, including platelet-derived growth factor receptor (PDGFR), and stem cell facto
'/>"/>

SOURCE Amgen
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Takedas Investigational PPI TAK-390MR Demonstrated Higher Healing Rates Compared to Lansoprazole as the Severity of Erosive Esophagitis Grade Increased, a New Integrated Analysis Showed
2. Takeda Submits a New Drug Application in the U.S. for Alogliptin (SYR-322) / ACTOS(R) (pioglitazone HCl) for the Treatment of Type 2 Diabetes
3. Takeda Doses First Patient in a U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia
4. Takeda Submits New Drug Application for Alogliptin (SYR-322) in the U.S.
5. Millennium Presents New Data on Investigational Drugs for Novel Cancer Targets at EORTC-NCI-AACR Symposium
6. University of Rochester Researcher Named Millennium Pharmaceuticals Career Development Scholar of The Leukemia & Lymphoma Society
7. Millennium Expands VELCADE(R) (Bortezomib) For Injection Program In Non-Hodgkins Lymphoma
8. Millennium Initiates Clinical Trial to EVOLVE the Treatment of Patients with Newly Diagnosed Multiple Myeloma
9. Cadence Pharmaceuticals Reports Third Quarter 2008 Financial Results and Provides Clinical Development Programs Update
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Mich. , Aug. 22, 2014  Diplomat, ... selected as one of two winners in the ... Specialty Pharmacy Solutions, LLC. The results of the ... of Specialty Pharmacy News. Diplomat ... Diplomat University Education & Training program. Through Diplomat ...
(Date:8/22/2014)... /CNW/ - On Aug. 20, at its annual meeting ... Association (CMA) voted on and approved a delegate resolution ... cannabis. Bedrocan Cannabis Corp., a leading Canadian licensed producer ... The CMA is quite right to point ... any plant material, including medicinal cannabis. While some patients, ...
(Date:8/22/2014)... , Aug. 22, 2014  Dr. Mark Rasak ... the Diamond Lifetime Achievement Award in the field of ... of Cardiovascular Clinical Associates. Dr. Rasak has ... all major aspects of the business; overseeing the daily ... primary coronary intervention. In addition, he is an honored ...
Breaking Medicine Technology:Diplomat honored as a Top Innovator by Specialty Pharmacy News 2Bedrocan Canada Statement Regarding Canadian Medical Association Motion on Smoking Marijuana 2Dr. Mark Rasak, MD is recognized by Continental Who's Who with the Diamond Lifetime Achievement Award 2
(Date:8/22/2014)... San Jose, CA (PRWEB) August 22, 2014 ... are now offering a new teeth whitening technique. Air ... during regular cleaning appointments. , Dark teeth can be ... into two categories: external stains and internal stains. External ... Internal stains can be caused by certain medications, such ...
(Date:8/22/2014)... found that targeted automated alerts in electronic health ... patients with urinary catheters. In addition, when the ... of improvement dramatically increased. , The alerts help ... in the first place and then alert them ... not been removed within a recommended time period. ...
(Date:8/22/2014)... August 22, 2014 Natural Clear Vision ... to restore his own vision from legally blind to perfect ... an investigative review. , “There is a huge portion ... for everyday function, and most people just think that’s the ... eye surgery that can be pretty risky at times,” reports ...
(Date:8/22/2014)... found in the circulating free tumor DNA (ctDNA) from ... patients correlates well with the EGFR mutations from patient-matched ... therapy is approved for EGFR activating mutation positive patients ... status is with DNA derived directly from tumor tissue, ... abundant and less invasive source of tumor DNA may ...
(Date:8/22/2014)... (PRWEB) August 22, 2014 Testosterone ... filed in U.S. courts on behalf of men ... their use of prescription low testosterone therapies, Bernstein ... new claim was filed against Pfizer Inc. on ... suffered life-threatening heart issues due to his use ...
Breaking Medicine News(10 mins):Health News:Japantown Dental Introduces Air Polishing 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 2Health News:Penn study: Electronic alerts significantly reduce catheter-associated urinary tract infections 3Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:High concordance between EGFR mutations from circulating-free tumor DNA and tumor tissue in non-small cell lung cancer 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 2Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 3Health News:Testosterone Treatment Lawsuit News: New Filing Alleges Depo-Testosterone Caused Life-Threatening Heart Problems, Bernstein Liebhard LLP reports. 4
... than those that are not. A new study says ... as celiac disease”// ,CD, also known as celiac ... to result from the activation of both a cell-mediated ... glutens (prolamins and glutenins) found in wheat, barley, rye, ...
... Chemistry and Industry magazine says that tropical plants imported ... dengue and other related illnesses. // ,The Asian ... and this species was detected in the Netherlands leading ... These mosquitoes were detected in imported bamboo in a ...
... dengue fever vaccine full of promise is being tried in ... the GlaxoSmithKline vaccine //have been completed in the US and ... finished by the end of next year, Dr. Hans L. ... interest in making the vaccine available fast, given that this ...
... with anti-TNF agents (etanercept) and chemotherapy drug methotrexate ... treatment of Rheumatoid Arthritis.// Furthermore, the progression of ... over three quarters of patients. The chronic nature ... for prevention of long-term joint damage in addition ...
... Aurobindo Pharma Ltd has announced that U.S. Food ... capsules USP 250 mg & 500 mg.// ... of bacterial infections such as bronchitis, tonsillitis, ear ... has achieved another major milestone by obtaining the ...
... conducted on nearly 50 nursery school children has revealed ... it on to their children as well, //resulting in ... were considerably higher amongst the group of children studied. ... children were greater than twice the normal levels in ...
Cached Medicine News:Health News:Breastfeeding: A Boon For Cealiac Disease 2Health News:Combination Therapy With ENBREL And Methotrexate Found Effective In RA Treatment 2Health News:Children’s Stress Levels Directly Related To Maternal Job Satisfaction 2
... Slit Lamp features easy-to-use controls to help ... to a halogen bulb that gives up ... with powers of 10X and 16X, the ... accepts commercially available C-mount cameras, allowing physicians ...
... uses state-of-the-art waveform analysis and ... a 65MHz rate to obtain ... and averages nine measurements and ... fits comfortably into the hand ...
Perfect for loading small volume samples onto agarose and polyacrylamide gels....
1000 L, Bulk Recommended for 500 and 1000 L pipettes...
Medicine Products: